Development of clinically viable non-muscle myosin II small molecule inhibitors
Cell · 2025-08 · 188 (17) · 4604-4621.e15
DOI: 10.1016/j.cell.2025.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2025-08. Verfasst von Laszlo Radnai und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology…. Hauptthemen laut MEDLINE: Myosin Type II, Small Molecule Libraries. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NINDS NIH HHS, Conseil National de la Recherche Scientifique.
Abstract (Originalsprache)
Non-muscle myosin II (NMII), a molecular motor that regulates critical processes such as cytokinesis and neuronal plasticity, has substantial therapeutic potential. However, translating this potential to in vivo use has been hampered by a lack of selective tools. The most prototypical non-selective inhibitor inactivates both NMII and cardiac muscle myosin II (CMII), a key regulator of heart function. Using rational drug design, we developed a series of NMII inhibitors that markedly improve tolerability by selectively targeting NMII over CMII, including MT-228 and clinical candidate MT-110. MT-228 and MT-110 have excellent properties, including high brain penetration and efficacy in preclinical models of methamphetamine use disorder (MUD), which has no current FDA-approved therapies. The structure of MT-228 bound to myosin II provides insight into its selectivity for NMII over CMII. The broad therapeutic windows of these NMII inhibitors provide valuable tools for the scientific community and a promising clinical candidate for the treatment of MUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Rese…
- Structural Motility, UMR 144 CNRS/Curie Institute, PSL Research University, Paris 75248, France.
- Department of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
- Myosin Therapeutics, Jupiter, FL 33458, USA.
- Curia, 26 Corporate Circle, Albany, NY 12203, USA.
- Department of Pharmacology & Therapeutics, Myology Institute, University of Florida, Gainesville, FL 32610, USA.
Förderung
- NIDA NIH HHS
- NINDS NIH HHS
- Conseil National de la Recherche Scientifique
- National Institute on Drug Abuse
- French National Research Agency
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Radnai, L., Young, E. J., Kikuti, C., Toth, K., Zhou, M., Hafenbreidel, M., Stremel, R. F., Lin, L., Pasetto, P., Jin, X., Patel, A., Conlon, M., Briggs, S. B., Heidsieck, L., Sweeney, H. L., Sellers, J., Krieger-Burke, T., Martin, W. H., Sisco, J., …, & Miller, C. A. (2025). Development of clinically viable non-muscle myosin II small molecule inhibitors. Cell, 188(17), 4604-4621.e15. https://doi.org/10.1016/j.cell.2025.06.006
Vancouver
Radnai L, Young EJ, Kikuti C, Toth K, Zhou M, Hafenbreidel M, et al. Development of clinically viable non-muscle myosin II small molecule inhibitors. Cell. 2025;188(17):4604-4621.e15. doi:10.1016/j.cell.2025.06.006
BibTeX
@article{Radnai2025,
author = {Radnai, Laszlo and Young, Erica J and Kikuti, Carlos and Toth, Katalin and Zhou, Minghai and Hafenbreidel, Madalyn and Stremel, Rebecca F and Lin, Li and Pasetto, Paolo and Jin, Xiaomin and Patel, Aagam and Conlon, Michael and Briggs, Sherri B and Heidsieck, Leïla and Sweeney, H Lee and Sellers, James and Krieger-Burke, Teresa and Martin, William H and Sisco, Jay and Young, Steven and Pearson, Paul and Rumbaugh, Gavin and Araldi, Gian Luca and Duddy, Steven K and Cameron, Michael D and Surman, Matthew and Houdusse, Anne and Griffin, Patrick R and Kamenecka, Theodore M and Miller, Courtney A},
title = {Development of clinically viable non-muscle myosin II small molecule inhibitors},
journal = {Cell},
year = {2025},
volume = {188},
number = {17},
pages = {4604--4621.e15},
doi = {10.1016/j.cell.2025.06.006}
}
EUVIMED